Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Total Current Liabilities (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Total Current Liabilities for 8 consecutive years, with $9.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Current Liabilities fell 37.72% to $9.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $9.8 million, a 37.72% decrease, with the full-year FY2024 number at $17.1 million, down 35.31% from a year prior.
  • Total Current Liabilities was $9.8 million for Q3 2025 at Whitehawk Therapeutics, up from $8.8 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $26.4 million in Q4 2023 to a low of $2.1 million in Q1 2021.
  • A 5-year average of $14.5 million and a median of $15.3 million in 2021 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 470.45% in 2022, then plummeted 60.46% in 2025.
  • Whitehawk Therapeutics' Total Current Liabilities stood at $15.3 million in 2021, then grew by 23.32% to $18.8 million in 2022, then surged by 40.14% to $26.4 million in 2023, then crashed by 35.31% to $17.1 million in 2024, then tumbled by 42.32% to $9.8 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Total Current Liabilities are $9.8 million (Q3 2025), $8.8 million (Q2 2025), and $12.3 million (Q1 2025).